Our lab uses viral vectors as a platform to deliver therapeutic genes to the injured nervous system. Recently, numerous non-invasive viral vectors which are able to cross the blood-brain barrier have been developed. Use of these vectors requires high titers and therefore an improved production process.
The implementation of our HEK293 Suspension Cell Procedure makes this AAV protocol less laborious compared to other adherent cell based systems, while at the same time gaining higher yields of AV vectors. There are no treatments to repair the damage in the central nervous system. We aim to use non-invasive viral vectors to stimulate central nervous system repair.
The advantage of this protocol is that we can now produce viral vectors at high yield, which allows us to perform non-invasive therapeutic gene delivery to the injured central nervous system. Our current work will pave the way to develop non-invasive gene therapy for multiple neurodegenerative diseases such as multiple sclerosis, Parkinson's and Alzheimer's disease.
